# NES BIOTECHNOLOGY Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nes-biotechnology-co

- Industry: Biotechnology
- Headquarters: Seoul, South Korea
- Website: www.nesbiotech.com
- Latest round: Seed (Mar 1, 2020)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2019, NES BIOTECHNOLOGY Co., Ltd. operates as a biotechnology company that develops therapeutic kits such as Nucleic Acid Delivery Kits, Antibody Delivery Kits, and Protein Delivery Kits to diagnose and treat infectious diseases, cancers, and hereditary diseases. In July 2021, NES BIOTECHNOLOGY raised KRW 3 billion in venture funding from Genomictree, Inc. As of July 2023, Kangseok Lee is the Chief Executive Officer (CEO) of the company.

NES BIOTECHNOLOGY Co., Ltd. specializes in the development of therapeutic biomolecules for many kinds of treatments, with nano blocks incorporated in their formulation. The company transports bioactive molecules by using a delivery system based on gold nanoparticles. This method enables medical professionals to safely administer personalized nucleic acids, proteins, and antibodies to cell lines and animals. Furthermore, the firm's technology acts as a shield for DNA, RNA, and protein therapeutics during transport to their intended targets, ensuring safe and efficient delivery into the specific cells for effective treatment.

## Funding rounds

- Seed, Mar 1, 2020 — KB Investment, Korea Tech Incubator for Startup

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Seed
- Korea Tech Incubator for Startup — Seed